{'fraction_non_alphanumeric': 0.01267605633802817, 'fraction_numerical': 0.0028169014084507044, 'mean_word_length': 6.5638297872340425, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Experience with the clinical use of lithium oxybutyrate in patients with cardiac rhythm disorders].

An antiarrhythmic effect of lithium oxybutyrate was demonstrated in 81% of patients with ventricular extrasystole in the presence of affective disturbances, those with hypersympathicotonus in particular. In arrhythmic cases, lithium oxybutyrate was shown to have a hypokinetic effect on central hemodynamics and contribute to peripheral vasodilatation without causing clinically apparent circulatory disorders. The drug inhibits platelet aggregation and moderately increases blood procoagulation activity in the presence of greater erythrocyte deformability and improved bulbar conjunctival microcirculation.